Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Raptor Pharmaceutica (RPTP) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 769,970
  • Shares Outstanding, K 85,310
  • Annual Sales, $ 94,240 K
  • Annual Income, $ -65,220 K
  • 36-Month Beta 1.18
  • Price/Sales 8.17
  • Price/Book 11.34
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.74
  • Most Recent Earnings -0.16 on 08/04/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.94 +0.67%
on 09/27/16
9.05 -0.55%
on 10/24/16
unch (unch)
since 09/23/16
3-Month
5.80 +55.17%
on 08/02/16
9.05 -0.55%
on 10/24/16
+2.94 (+48.51%)
since 07/22/16
52-Week
2.94 +206.12%
on 01/20/16
9.05 -0.55%
on 10/24/16
+3.39 (+60.43%)
since 10/23/15

Most Recent Stories

More News
Horizon Pharma plc Completes Acquisition of Raptor Pharmaceutical Corp.

- Adds Two Rare Disease Medicines and Further Diversifies Company Revenue -

How These Biotech Stocks are Faring? -- Raptor Pharma, Amicus Therapeutics, Neuralstem, and Macrocure

Pre-market this morning Stock-callers.com looks at the performances of these four Biotech stocks: Raptor Pharmaceuticals Corporation (NASDAQ: RPTP), Amicus Therapeutics Inc. (NASDAQ: FOLD), Neuralstem...

Horizon Pharma plc Announces Pricing of Private Offering of Senior Notes

Horizon Pharma plc (Nasdaq:HZNP) ("Horizon"), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines...

Horizon Pharma plc Announces Proposed Private Offering of Senior Notes and Intention to Borrow Incremental Term Loans under its Existing Senior Secured Credit Facility

Horizon Pharma plc (Nasdaq:HZNP) ("Horizon"), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines...

Horizon (HZNP) Stock Down on Dull Q3 View; Cuts '16 Outlook

Horizon's (HZNP) shares took a beating after the company reported weak Q3 results and a dismal 2016 outlook.

Global Lysosomal Storage Diseases Therapeutics Market is Estimated to be Valued at US$ 14.36 Bn by 2026 - Persistence Market Research

NEW YORK, October 12, 2016 /PRNewswire/ --

Global Lysosomal Storage Diseases Therapeutics Market is Estimated to be Valued at US$ 14.36 Bn by 2026 - Persistence Market Research

Shire PLC, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., and Amicus Therapeutics, Inc. are Some of the Companies Operating...

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Raptor Pharmaceutical Corp. (RPTP)

Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) in the United States District Court for the...

Exelixis Elects Julie Anne Smith to Its Board of Directors

Exelixis, Inc. (NASDAQ: EXEL) today announced that accomplished biopharmaceutical executive Julie Anne Smith has been elected to the company's Board of Directors. Ms. Smith's appointment...

SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Raptor Pharmaceutical Corp. -RPTP

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Raptor Pharmaceutical Corp. ("Raptor" or "the Company") (Nasdaq- RPTP-News) for...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Raptor Pharmaceutical Corp. is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where...

See More

Support & Resistance

2nd Resistance Point 9.10
1st Resistance Point 9.05
Last Price 9.00
1st Support Level 8.95
2nd Support Level 8.90

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.